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Résumé  
Les tumeurs des cellules de la granulosa (GCTs) sont des tumeurs avec un potentiel 
malin ayant tendance à récidiver, provoquant ainsi la mort dans 80% des cas de stade avancé 
consécutif à une rechute.  Bien que les GCTs représentent 5% des tumeurs ovariennes, peu 
d’études ont évalué les protocoles de traitement adjuvant pour la maladie avancée ou 
récurrente.  Notre but était d’évaluer l’efficacité de la voie de signalisation du facteur de 
croissance de l’endothélium vasculaire A (VEGFA) comme cible pour le traitement de la GCT 
utilisant le modèle murin transgénique Ptentm1Hwu/tm1Hwu; Ctnnb1tm1Mmt/+; Amhr2tm3(cre)Bhr/+ 
(PCA) qui reproduit le stade avancé de la maladie humaine.  Un anticorps anti-VEGFA a été 
administré une fois par semaine par voie intrapéritonéale (IP) à partir de 3 semaines d’âge.  La 
thérapie anti-VEGFA a permis une réduction de la taille des tumeurs à 6 semaines d’âge 
(p<0.05) et une prolongation de la survie des animaux traités, lorsque comparé aux animaux 
contrôles. L’analyse des GCTs a montré une réduction significative de la prolifération 
cellulaire (p<0.05) et de la densité microvasculaire (p<0.01) mais aucune différence 
significative n’a été détectée dans l’apoptose cellulaire.  p44/p42 MAPK, un effecteur de la 
signalisation pour le récepteur 2 de VEGFA (VEGFR2) associé à la prolifération cellulaire, 
était moins activé dans les tumeurs traitées (p<0.05).   Par contre, l’activation d’AKT, un 
effecteur impliqué dans la survie cellulaire, était similaire d’un groupe à l’autre.  Ces résultats 
suggèrent que l’anticorps anti-VEGFA réduit la prolifération cellulaire et la densité 
microvasculaire chez les souris PCA par inhibition de la voie de signalisation VEGFR2-
MAPK, inhibant ainsi la croissance tumorale.  En conclusion, l’efficacité de la thérapie anti-
VEGFA mérite d’être évaluée en essais contrôlés randomisés pour le traitement des GCTs 
chez l’homme.     
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Abstract  
Ovarian granulosa cell tumors (GCTs) are potentially malignant tumors that have a 
tendency for late recurrence and cause death in 80% of women with advanced GCT due to 
recurrent disease.  Although GCTs represent 5% of ovarian tumors in women, few studies 
have evaluated adjuvant treatment protocols for advanced or recurrent disease.  Our goal was 
to determine the potential of targeting the vascular endothelial growth factor A (VEGFA) 
signaling pathway for the treatment of GCT.  We used a genetically engineered mouse model, 
Ptentm1Hwu/tm1Hwu; Ctnnb1tm1Mmt/+; Amhr2tm3(cre)Bhr/+ (PCA), which imitates the advanced human 
disease.  A monoclonal anti-VEGFA antibody was administered by intra-peritoneal injection 
once a week beginning at 3 weeks of age.  Anti-VEGFA therapy significantly decreased tumor 
weights by 6 weeks of age (p<0.05) and increased survival in treated animals in comparison to 
controls.  Significant decreases in tumor cell proliferation (p<0.05) and microvessel density 
(p<0.01), but no significant difference in apoptosis was found in PCA tumors.  p44/p42 
MAPK, a VEGFA receptor 2 (VEGFR2) signaling effector associated with cell proliferation, 
was significantly less activated in anti-VEGFA-treated tumors (p<0.05).  In contrast, AKT 
activation, a VEGFR2 signaling effector associated with cell survival was similar among all 
groups.  These results suggest that anti-VEGFA therapy effectively reduces cell proliferation 
and microvessel density in PCA mice by inhibition of the VEGFR2-MAPK pathway, resulting 
in inhibition of GCT growth.  We conclude that anti-VEGFA therapy merits further 
investigation in the form of controlled randomized trials for the treatment of human GCT.  
 
Keywords: granulosa cell tumor, anti-VEGFA therapy, angiogenesis, adjuvant therapy, 
preclinical mouse model, AKT signaling, MAPK signaling 
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Introduction 
 Cancer is a comprehensive term that encompasses over one hundred diseases that all 
share in common the transformation of normal human cells into malignant (cancer) cells (1, 
2).  Initially, a succession of genetic changes occurs that confer growth advantages to given 
cells, leading to their conversion to cancer cells and ultimately tumor development (2).  In 
contrast to normal cells, cancer cells are able to sustain proliferation, evade tumor suppression, 
resist apoptosis, replicate indefinitely, induce angiogenesis, and invade and form metastases 
(3).  These acquired alterations in cell physiology are what dictate tumor growth in 
combination with signals from the tumor microenvironment and inflammatory mediators (2, 
4).   
 Many different types of cancer affect the female reproductive system, with ovarian 
cancer being the leading cause of death among gynecological cancers and representing 3% of 
all cancers in women (1).  Three categories of ovarian tumors exist with each one named 
according to its derived cell type (5).  80-90% of ovarian tumors are epithelial ovarian tumors, 
followed by sex cord-stromal tumors (SCSTs), which make up 7-8%, and the remaining 1-3% 
are germ cell tumors (5, 6).  Within the category of SCSTs, a given tumor will contain sex 
cord and stromal components of the developing gonad that may include one or a combination 
of granulosa cells, theca cells, lutein cells, Sertoli cells, Leydig cells, or fibroblasts (7).  The 
majority are granulosa cell tumors (GCTs), accounting for 70-90% of SCSTs and 
approximately 5% of all ovarian tumors (6, 8-10).  GCTs are considered as potentially 
malignant tumors characterized by insidious growth and late recurrence (6, 8, 11, 12).    
 Although some studies have investigated GCT pathogenesis, the mechanisms 
mediating GCT development remain unclear.  One factor that has been identified as a crucial 
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component of GCT disease is angiogenesis, as these are highly vascularized tumors that 
express high levels of vascular endothelial growth factor (VEGF), a key mediator of tumor 
angiogenesis (11, 13, 14).  Based on this, angiogenesis was proposed as a therapeutic target 
for the adjuvant treatment of GCT (11, 13-16).   
 Animal models can serve as useful tools to evaluate the efficacy of novel therapeutic 
agents and targets.  A genetically engineered mouse model that develops GCT that imitates the 
advanced disease in women was generated and served as a preclinical model for investigating 
a novel therapeutic agent that targets VEGF. 
 This thesis will present the evaluation of an anti-angiogenic therapy for the treatment 
of GCT in our mouse model.  First off, a review of ovarian and GCTs in women will be 
presented, followed by current knowledge of GCT pathophysiology.  Next, descriptions of the 
existing transgenic mouse models of GCT will be given, followed by a presentation of 
angiogenic inhibitors.  Finally, the findings from this study will be presented and discussed.         
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Literature Review 
 
Chapter 1: Ovarian Cancer 
 
1.1. Ovarian tumors in women 
The American Cancer Society estimates that 22,280 women will be newly diagnosed 
with ovarian cancer in 2012, of which 15,500 will die from it in the United States alone (1).  
Ovarian cancer is the leading cause of death among gynecological cancers, accounting for 3% 
of all cancers in women (1).   
Ovarian tumors are classified into three major groups based on histological patterns 
and cell types; the most common and best described are epithelial ovarian tumors (80-90% of 
cases), followed by SCSTs (7-8%), and finally germ cell tumors (1-3%) (5, 6).  Accounting 
for 70-90% of SCSTs are GCTs, which represent approximately 5% of all ovarian tumors and 
are derived from the hormonally active component of the ovarian stroma, the granulosa cell (6, 
8-10, 17).  The reported incidence of GCT is 0.58 to 1.6/100,000/year (18).   
 
1.2. Granulosa cell tumors in women 
 
1.2.1. Forms 
 Although GCTs are considered to be rare, they are potentially malignant, tend to recur 
over long periods, and are therefore of clinical importance (8, 11, 12). They are divided into 
the adult (95%) and juvenile forms (5%) based on clinical presentation and histological 
characteristics (8, 18).  The adult form mostly occurs in post-menopausal women with the 
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median age at presentation being 50-54 years old (17) and is characterized by well and poorly 
differentiated histological patterns with coffee-bean grooved nuclei (6).  On the other hand, 
the juvenile form mostly affects women less than 30 years of age (mean 13-17 years) and is 
characterized by large luteinized cells with hyperchromatic nuclei lacking nuclear grooves (6, 
8, 18).  Both the adult and juvenile form have been reported in children and adults, 
respectively (8, 17, 18).   
 
1.2.2. Clinical presentation  
GCT cells share morphological, biochemical, and hormonal features of normal 
proliferating pre-ovulatory granulosa cells (19, 20).  Approximately 70% of GCTs produce 
hormones that include estradiol, inhibin, and anti-Müllerian hormone (AMH) that are 
responsible for a variety of nonspecific symptoms such as abdominal pain, distension, 
bloating, and abnormal uterine bleeding (6, 8,18).  Other symptoms may include menstrual 
irregularities, post-menopausal bleeding, abdominal discomfort, weight loss, presence of a 
pelvic or abdominal mass, and breast enlargement or tenderness (18). Abnormal uterine 
bleeding and abdominal pain have been reported as the most common presenting symptoms 
(18, 21).  The tumor mass may compress adjacent organs and cause dysuria and constipation 
(8).  Ascites occurs in 10-28.8% of cases (8, 18, 22).  Complications, such as ovarian torsion, 
haemorrhage, or cystic rupture, often manifest as acute abdominal pain and distension (8, 18). 
Unfortunately, 12.5-14.3% of patients are asymptomatic and are only diagnosed during routine 
examinations (21, 22).   
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Specific to the juvenile form, 80-90% of patients 8 years of age or less present with 
isosexual precocious pseudopuberty, characterized by precocious breast development, 
increased pubic hair, vaginal bleeding, and advanced growth (6, 8, 18).   
Some pathological conditions have been associated with GCT and include endometrial 
hyperplasia in 25-50% of women (due to estrogen stimulation of the endometrium), 
endometrial adenocarcinoma in 8-13% of women over the age of 45, breast cancer in 3% of 
women, and infertility in 22% of women of childbearing age (8, 18).  The juvenile form has 
been associated with Potter’s syndrome, multiple congenital abnormalities, Ollier’s disease, 
and Maffucci’s syndrome (18).  
 
1.2.3. Diagnosis 
  Initial diagnosis is based on clinical features and pelvic examination (8). As the 
majority of GCTs produce oestrogens that are responsible for various symptoms, this often 
allows for early detection (17).  At diagnosis, many GCTs have already attained a considerable 
size (average diameter of 12 cm), 95% of cases are unilateral, 85-95% are palpable, and 78-
91% are at stage I/IV (i.e. confined to the ovary(ies); according to FIGO classification) (8, 17, 
18, 23).   
The tumors may appear as a solid mass with hemorrhagic or fibrotic changes, as 
completely cystic, or with multilocular cystic lesions (18).  One classification type categorizes 
adult-type GCT based on morphologic patterns as either multilocular cystic, thick-walled 
unilocular cystic, or thin-walled unilocular cystic, homogenously solid or heterogeneously 
solid (24).   
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Diagnostic tools include ultrasound, which provides qualitative information about the 
mass, such as size, echogenicity, and consistency however, CT and MRI are more sensitive 
exams (8, 17).  Uterine biopsy is indicated in cases of postmenopausal bleeding in order to 
exclude adenocarcinomas (17).  
Final diagnosis of GCT is based on histopathology examination (8).  Malignant GCTs 
resemble normal granulosa cells but with round to oval nuclei and coarsely stippled chromatin.  
Cytoplasm is often faintly eosinophilic and vacuolated.  GCTs demonstrate a high degree of 
cellular polymorphism and a high mitotic rate with focal areas of necrosis and hemorrhage, 
and evidence of local invasion (25). 
 
1.2.4. Serum tumor markers 
Many serum tumor markers have been proposed for the management and surveillance 
of GCT, although very few are specific (8).  The most relevant markers include: inhibin, 
estradiol, and anti-Müllerian hormone (6, 8, 17, 26).  
 
1.2.4.1. Inhibin 
Inhibin is a member of the transforming growth factor (TGF)-! family that is 
synthesized by normal granulosa cells.  It is mostly secreted during the follicular phase of the 
menstrual cycle and acts by suppressing the synthesis and secretion of follicle-stimulating 
hormone (FSH) (17, 18).  Patients with GCT tend to have elevated inhibin serum 
concentrations (mostly inhibin B), which has been positively correlated with tumor size (26) 
and therefore serve to detect GCT and estimate tumor bulk (6).  As inhibin levels drop after 
tumor removal, they also serve to predict and detect recurrence (6, 26, 27).  Serum inhibin 
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levels also drop in postmenopausal women (secondary to the depletion of ovarian follicles), 
which may serve as a comparative baseline in these women (6, 28).  It is important to note, 
however, that elevated inhibin levels are not specific for GCT, and may be elevated in 
epithelial ovarian tumors (17).  
 
1.2.4.2. Estradiol 
Estradiol is mostly produced by granulosa cells during the reproductive period in 
women (6).  In the majority of GCTs, estradiol is secreted in large amounts and is responsible 
for many of the tumor-related symptoms (6).  Although estradiol might seem like a logical 
tumor marker for GCT, no correlation between estradiol levels and GCT progression or 
recurrence has been found (29, 30). This could be due to the fact that estradiol production 
depends on its precursor, androstenedione, produced by theca cells and in the absence of theca 
cells in some GCTs, no estradiol is secreted (6, 17, 29).  On the whole, estradiol is not 
considered to be a reliable tumor marker for GCT, especially in comparison to inhibin B and 
AMH (6, 17, 29).   
 
1.2.4.3. Anti-Müllerian hormone 
AMH is another member of the TGF! superfamily that is expressed by granulosa cells 
and controls the formation of primary follicles during reproductive life, but is virtually 
undetectable after menopause (17, 28).  Serum AMH levels were found to be elevated in the 
majority of patients with GCT, undetectable in patients with clinical remission, and elevated 
several months prior to clinical recurrence (30, 31).  In a recent review, inhibin B and AMH 
8 
!
were both found to be useful serum markers for diagnosis and surveillance of patients with 
GCT (32).   
 
1.2.5. Current treatment 
Initial management of GCT involves cytoreductive surgery, which allows for staging, 
definitive diagnosis, and tumor debulking (8, 17, 18).  For women beyond childbearing age, 
total hysterectomy and bilateral salpingo-oophorectomy are attempted (8, 18).  For women of 
childbearing age who wish to preserve fertility, a unilateral salpingo-oophorectomy is 
performed, provided that the disease is contained within one ovary (8).  In these instances, 
conservative surgery is often complemented by careful staging and endometrial biopsy to rule 
out uterine cancer (17, 18).    Staging normally includes a partial omentectomy, evaluation of 
para-aortic and pelvic lymph nodes, peritoneal biopsies, and peritoneal washing cytology (8, 
17).  If the biopsies are disease free, no further treatment is required. 
Adjuvant treatment is recommended for patients with recurrent or advanced disease; 
essentially for patients with stages II-IV disease or stage I disease associated with large tumor 
size, high mitotic index, or tumor rupture (8, 17).  Standardized adjuvant treatment protocols, 
however, have yet to be established.  Adjuvant therapies include: chemotherapy, radiation 
therapy, hormonal therapy, and more recently, anti-angiogenic therapy.   
 
1.2.5.1. Chemotherapy 
GCT is generally responsive to chemotherapy, which is mostly platinum-based, with 
bleomycin/etoposide/cisplatin (BEP) being the most frequently used regimen (8, 17, 19).  
Chemotherapy is indicated for advanced, inoperable, or recurrent disease, when surgery or 
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radiotherapy is not a viable option (18).  In a retrospective study by Park et al (19), 13 patients 
diagnosed with advanced GCT had undergone cytoreductive surgery followed by 6 cycles of 
adjuvant chemotherapy with BEP.  None of the patients who received the full 6 cycles of BEP 
had recurrent disease with a 5-year disease-free survival rate of 100% (19).  Secondary effects 
to the BEP regimen are non-negligible however, and include myelotoxicity and a risk of 
secondary acute myelogenous leukemia (18).     
 
1.2.5.2. Radiation therapy 
Radiation therapy is indicated as an adjuvant treatment or for recurrent disease (18).  
Although it has been associated with improved survival in a few studies (33-35), other studies 
have found no survival advantage (36-38).  In a retrospective study by Hauspy et al (34), 31 
patients diagnosed with GCT had received adjuvant radiotherapy.  They found a significantly 
longer disease free survival in patients who had received radiation therapy (251 months) in 
comparison to patients who had not (112 months, p=0.02) (34). In contrast, Malmström et al 
(36) found no survival benefit in 48 GCT patients treated with radiation therapy.  Due to the 
retrospective nature of these studies, too many variables could have potentially confounded 
the real efficacy of radiation therapy for the treatment of GCT; large-scale prospective trials 
would be required in order to elucidate its role in the treatment of recurrent disease or as an 
adjuvant treatment for GCT.    
 
1.2.5.3. Hormonal therapies 
Hormonal therapies include gonadotropin releasing hormone (GnRH) agonists, GnRH 
antagonists, progestogens, and anti-oestrogens (8).  A limited number of case reports have 
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evaluated their efficacy in the adjuvant treatment of GCT and most often describe last resort 
attempts in cases of recurrent disease (6).  While some studies have shown hormonal therapy 
to result in stabilized disease, prolonged remission, partial response, and no major side effects 
(18, 39-42), others show no response whatsoever (43, 44).  Although these therapies may 
indeed be effective in slowing down the progression of GCT disease, it is not possible to draw 
any reliable conclusions from a handful of case reports.  In addition, the fact that the majority 
of patients were in the final stages of disease and several other treatment options had 
previously been attempted, it is difficult to attribute the precise contribution of hormonal 
therapy to the observed effects.   
 
1.2.6. Recurrence and survival  
As GCT is often diagnosed at an early stage, survival is considered excellent (17).  
Still, 80% of cases diagnosed with advanced-stage GCT will die from recurrent disease (45). 
GCTs can spread locally by direct extension and intraperitoneal seeding to ovarian 
serosa, omentum, fallopian tube, and pelvic walls or by hematogenous or lymphatic routes to 
reach the lungs, liver, brain, skeleton, diaphragm, abdominal wall, and adrenal glands to form 
metastases (8, 18).  
GCT has a reputation for recurrences over long periods, with 40 years being the 
longest time period of recurrence ever recorded (46).  In one study (22), recurrence rate was 
5.4% for stage I, 21.1% for stage III, and 40% for stage IV disease; overall recurrence rates 
vary between 11.2-21% (8, 9, 21).  Recurrences are thought to originate from peritoneal seeds, 
which are points of contact between the primary tumor and abdominal or pelvic structures that 
remain after removal of the primary tumor and grow very slowly.  For this reason, recurrences 
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most often occur in the abdomen or pelvis and tend to occur between 5 to 10 years after initial 
diagnosis and treatment (8, 18). 
Many predicting factors for recurrence and poor survival have been identified and 
include: advanced stage at diagnosis, high mitotic index (>10 mitoses/10 HPF), bilaterality, 
large tumor size (>5cm), tumor rupture, lymphatic system invasion, nuclear atypia, absence of 
call-exner bodies, presence of residual disease, DNA ploidy, and age (50+) (8, 17-19, 47).  
Stage is universally accepted as the most important prognostic factor (17, 22, 28) with a 5-year 
survival of 90-100% for stage I disease, 55-75% for stage II, and 22-50% for stage III and IV, 
and a 10-year survival of 84-95% for stage I, 50-65% for stage II, and 17-33% for stage III/IV 
(18).  VEGF has also been identified as a prognostic factor.  Brown et al (48) showed that 
increased microvessel density and overexpression of VEGF correlated with the presence of 
distant metastasis and shorter survival in patients with SCSTs. Many other prognostic factors 
are mentioned in the literature, but have not been consistently reported.   
Following diagnosis and treatment, regular examination is recommended every three 
months for the first two years, and then every four to six months for five years.  Afterwards, 
examinations should be continued for life, as late recurrences tend to occur, and normally 
include a physical examination, ultrasound, CT scan, and evaluation of tumor markers (8).     
 
Chapter 2: Pathophysiology of GCT   
 
2.1. Etiology  
 Little is known about the etiology of GCT despite the fact that a number of studies 
have attempted different approaches to elucidate this.  A few studies have examined the GCT 
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karyotype in order to identify abnormalities (6, 27, 49-51).  Another approach has been to 
focus on pathways involved in normal folliculogenesis, as GCTs display many features of 
proliferating pre-ovulatory granulosa cells, such as FSHR expression, FSH binding, estrogen 
synthesis, GATA-4 expression, and inhibin expression and synthesis (6, 20, 27).  Others have 
studied pathways, oncogenes and tumor-suppressor genes that have frequently been implicated 
in many cancer types (6, 12, 27, 52-57).  
 
2.1.1. Cytogenetic abnormalities 
A distinctive pattern of chromosomal aberrations has been detected in 5-20% of 
aneuploid GCTs (6, 49).   Trisomy 12 has been observed in 14-33% of cases, trisomy 14 in 
25-33%, and monosomy 22 in 35-40% (6, 27, 49-51).  Although several important genes have 
been identified on chromosome 12 such as KRAS 2, KRAG, MDM2 and on chromosome 14 
such as FOS, BCL2L2, TGR!3, their precise role in GCT pathogenesis is unclear (49).   
 
2.1.2. Molecular genetics of GCT  
 
2.1.2.1. FSH signaling pathway 
Although GCTs express high levels of the FSHR gene, no activating mutations in the 
FSHR or its associated G proteins have been identified (6, 27).  Instead, it is suspected that 
activating mutations in genes encoding signaling effectors downstream of the FSHR, 
involving extracellular regulated kinases (ERK) or phosphoinositide 3-kinase (PI3K)/AKT 
signaling cascades might be involved (Figure 1) (6, 27, 58).  Although mutation of the PI3K 
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subunit genes or inactivation of tumor suppressor phosphatase and tensin homolog (PTEN) has 
been implicated in epithelial ovarian tumors, Bittinger et al (59) found no association in GCT.   
 
 
 
2.1.2.2. Estrogen receptors 
Estrogen synthesis is a crucial part of folliculogenesis with expression of estrogen 
receptor genes (ESR1 and 2) occurring during the proliferative phase in human granulosa cells 
(27).  ESR2 was found to be predominantly and abundantly expressed in GCTs, in comparison 
to ESR1 (27, 60).  As approximately 70% of GCTs produce estrogens, it is suspected that 
these receptors might play a role in stimulating granulosa cell growth and differentiation (20).   
 
2.1.2.3. GATA-4 expression 
Another feature of proliferating granulosa cells is GATA-4 expression.  GATA-4 is a 
member of the GATA family of transcription factors that regulates the expression of many 
Figure 1 
 
FSH receptor downstream signaling 
effectors.  FSH binding to its receptor 
FSHR activates both the ERK1/2 and 
PI3K/AKT intracellular signaling pathways 
in granulosa cells.  AKT = protein kinase 
B, ERK = extracellular regulated kinase, 
FSH(R) = follicle stimulating hormone 
(receptors), MEK = ERK kinase, PDK = 
phosphatidylinsitol-dependant kinase, 
PI3K = phosphoinositide 3-kinase, PTEN = 
phosphatase and tensin homolog.  
 
Adapted from Jamieson & Fuller 2012 and 
Laguë et al 2008.!
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important genes in the gonads, whose expression was found to be activated in primary follicles 
in conjunction with the activation of granulosa cell proliferation (61).  Anttonnen et al (61) 
reported high levels of GATA-4 in 44% of primary GCTs and a significant positive correlation 
between GATA-4 expression and clinical stage and risk of recurrence.  This group later 
reported a correlation between GATA-4 expression and Bcl-2, an anti-apoptotic gene 
controlled by GATA-4 (62).  The authors suspect that an increase in GATA-4 expression up-
regulates Bcl-2 activation thereby promoting granulosa cell survival and inhibiting apoptosis 
in GCT tumorigenesis (62).  
 
2.1.2.4. Inhibin expression and synthesis 
Serum inhibin levels are elevated in women with GCT and have been associated with 
suppressed FSH levels, indicating a biologically active form of inhibin (6, 63).  In contrast, in 
an inhibin-deficient mouse model, SCSTs developed in 100% of animals (64).  Matzuk et al 
(64, 65) explained this apparent contradiction by the development of resistance to inhibin in 
the human disease, whose normal role may be tumor suppression specifically in the gonads.       
 
2.1.2.5. WNT/!-catenin signaling pathway 
Another pathway that has been implicated in several cancer types is the WNT/!-
catenin signaling pathway (52).  Boerboom et al (52, 53) evaluated the WNT/!-catenin 
pathway that is normally expressed in ovarian granulosa cells and found hyperactivation in a 
subset of human and equine GCTs.  In order to confirm whether activation of the WNT/!-
catenin signaling pathway was in fact involved in GCT development, this group developed a 
mouse model expressing a dominant stable !-catenin mutant (52). The majority of animals did 
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in fact develop ovarian lesions at an advanced age that were confirmed as GCTs (52).  These 
findings were the first to demonstrate a causal link between altered WNT/!-catenin signaling 
and GCT tumorigenesis (53), and later served to develop the mouse model that is the focus of 
this paper. 
 
2.1.2.6. Oncogenes and tumor-suppressors genes 
 Several oncogenes that have been implicated in a range of tumors have also been 
examined for their potential role in GCT pathogenesis however, these investigations have 
yielded few novel insights.  No mutation or overexpression was found in the following 
oncogenes: c-myc, p21-ras, c-erbB2, K-ras, N-ras, H-ras, B-raf, or WT1 (6, 12, 54, 55).  
Neither mutation nor loss of tumor-suppressor p53 was found to be implicated in GCT (27, 56, 
57).  The inability to identify oncogenes and tumor-suppressor genes that might be responsible 
for initiating the development of GCT represents a further delay in the development of 
effective treatment agents, as many current cancer drugs specifically target the proteins 
encoded by oncogenes (66).   
 
2.1.2.7. FOXL2 mutation 
The most significant breakthrough in GCT pathogenesis came in 2009 when Shah et al 
(67) identified a somatic missense point mutation in FOXL2 402C"G (C134W) in 97% of 
adult GCTs.  The FOXL2 gene encodes a member of the forkhead domain/winged-helix 
family of transcription factors that is specifically expressed in ovarian follicular cells and is 
crucial for granulosa cell function and follicle development (6). This mutation is almost 
entirely absent in other cancer types, such as epithelial ovarian, breast, and even juvenile 
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GCTs (67, 68).  Several subsequent studies confirmed the mutation in adult-type GCT with an 
overall occurrence of 94% (6).  These findings strongly suggest that FOXL2 mutation is 
pathognomonic for adult-type GCT and that it constitutes either an activating or a gain-of-
function mutation (6, 67, 69).  
In an attempt to explain the mechanism of tumorigenesis driven by the FOXL2 
mutation, studies have evaluated FOXL2 targets, such as the aromatase gene CYP19A1 (69).  
FOXL2 induces CYP19A1 which leads to increased estrogen conversion by granulosa cells 
(69).  Fleming et al (70) confirmed that aromatase is a direct target of FOXL2 (C134W) in 
adult-type GCT and more specifically, that the mutation altered the regulation of the 
aromatase promoter (6).  As hyperestrogenism is seen in approximately 70% of adult-type 
GCTs, deregulated activity of FOXL2 via altered aromatase activity might contribute to the 
development of this condition (6, 69).   
In a FOXL2 knockout mouse model, increased follicular loss and oocyte atresia were 
found, which suggests that FOXL2 plays an anti-apoptotic role (69, 71).  This finding was 
supported by Kim et al (72), who demonstrated that mutant FOXL2 exhibited minimal cell 
death in comparison to the wild-type.  These findings suggest a tumor suppressor role for 
FOXL2 in normal granulosa cells, which in the mutant form, is impaired and incapable of 
mediating death ligand-induced apoptosis (72).  
 In juvenile-type GCT, FOXL2 expression is decreased or absent and has been 
associated with aggressive or advanced stage disease (6, 68).   
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2.2. Angiogenesis 
In 1971, Judah Folkman (73) hypothesized that tumor growth depends on the 
formation of new blood vessels from pre-existing ones, a concept coined as angiogenesis, and 
proposed angiogenesis as a therapeutic target for cancer treatment.  Angiogenesis is now 
known to be crucial for tumor growth, as small tumor masses are unable to grow beyond 1-2 
mm without a blood vessel supply to support their growth (74). Early during tumor 
development, an angiogenic switch occurs in which quiescent tumor endothelial cells are 
activated (75, 76).  Tumor cells release pro-angiogenic mediators that bind to adjacent 
vascular endothelial cells and stimulate the formation of new blood vessel capillaries that 
infiltrate the tumor mass (74).  This infiltration allows the microscopic tumor mass to expand 
because tumors, just like normal tissues, require oxygen, nutrients, and the evacuation of 
carbon dioxide and metabolic waste (3).  This neovascularization also allows the tumor to 
eventually form metastases (74).   
Tumor blood vessels tend to be aberrant, characterized by precocious capillary 
sprouting, convoluted and excessive vessel branching, distorted and enlarged vessels, erratic 
blood flow, micro-hemorrhaging, leakiness, and abnormal levels of endothelial cell 
proliferation and apoptosis (3, 77, 78).   
 
2.2.1. Regulation of angiogenesis 
The angiogenic process depends on interactions between vascular endothelial cells, 
tumor cells, inflammatory cells, the surrounding micro-environment, and many auxiliary 
factors (79).  Numerous environmental factors stimulate VEGF expression, a major mediator 
of angiogenesis, which include hypoxia, low pH, hormones, growth factors, and cytokines (74, 
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75, 80-84).  Mutations in oncogenes and/or tumor suppressor genes also contribute to 
upregulating VEGF (74, 85).  Negative regulators play essential roles in keeping angiogenesis 
under control, and include: thrombospondin, endostatin, tumstatin, vasostatin, and vasohibin 
(84).   For the purposes of this study, the remainder of this review will focus on the VEGF 
pathway, as it represents the major regulatory pathway involved in tumor angiogenesis (83, 
84).  
 
2.2.2. Vascular endothelial growth factor  
 In 1989, Napoleone Ferrara (86) purified VEGF, a key mediator in angiogenesis, 
vasculogenesis, and lymphangiogenesis during embryonic and post-natal development (82).  
The VEGF family is made up of five members, with VEGFA, being the best-characterized and 
the most important activator of vascular endothelial cells (76, 79, 80, 84, 87).  VEGFA is a 
homodimeric glycoprotein made up of two identical 23 kDa subunits (82). Alternative exon 
splicing of the VEGFA gene generates various isoforms, with VEGF165 being the predominant 
and most mitogenic isoform, that is frequently overexpressed in many tumor types, including 
colon, renal cell, and ovarian cancer (79, 80, 82, 83).   
 VEGFA signals via two cell surface receptor tyrosine kinases (RTK), VEGFR1 (Flt-1) 
and VEGFR2 (Flk-1 in mice/KDR in humans), which are chiefly expressed in endothelial cells 
(Figure 2) (13, 14, 76, 80, 82, 83, 88).  The receptors possess seven extracellular 
immunoglobulin-like domains and an intracellular tyrosine kinase domain (88).  VEGFR2 is 
the dominant pro-angiogenic receptor and upon VEGF binding, VEGFR2 undergoes 
dimerization and tyrosine kinase auto-phosphorylation, which activates downstream signaling 
pathways involved in vascular endothelial permeability, proliferation, migration, and survival 
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(14, 79, 82, 83, 87).  Some of these pathways include ERK1/2 and PI3K/AKT (80).  VEGFR2 
is also strongly expressed in some tumor cells (e.g. granulosa) (13).  VEGFR1, on the other 
hand, is suspected to be a decoy receptor that sequesters VEGF and prevents binding to 
VEGFR2 (83, 84, 89).   
 
 
 
 
 
2.2.3. Other roles for VEGF in tumorigenesis 
Although VEGF’s role in tumor growth and metastasis has mostly been attributed to its 
angiogenic activity, VEGF has recently been implicated in other tumorigenic functions as 
well.  VEGF is suspected of playing an immunosuppressive role in cancer development (74, 
Figure 2.  VEGFR2 signaling pathway in endothelial cells.  VEGFA binding to its main 
receptor VEGFR2 activates downstream effectors involved in vascular endothelial cell 
proliferation, migration, permeability, and survival.  VEGFR1 may be a decoy receptor that 
prevents VEGFA binding to VEGFR2.  AKT = protein kinase B, ERK = extracellular regulated 
kinase, PI3K = phosphoinositide 3-kinase.  
 
Adapted from Ferrara and Kerbel 2005. 
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90), as well as directly promoting tumor growth by binding to its receptors expressed on tumor 
cells (91).  VEGF increases the permeability of tumor microvasculature, which contributes to 
reshaping the extracellular matrix (leading to cell migration and proliferation), forming 
ascites, and forming metastases by allowing tumor cells to disseminate through the leaky 
capillaries (76).    
 
2.2.4. VEGF and GCT  
Angiogenesis is suspected to play an important role in the development and 
progression of the highly vascularized GCTs and its key mediator, VEGF, has been identified 
as an important component of this disease (11, 13, 14).  Schmidt et al (92) found VEGF 
expressed in 94% of GCT specimens and none in the controls.  Similarly, Färkkilä et al (13) 
found VEGF expressed in 93% of GCTs and VEGFR2 highly expressed in 82% of tumors, in 
both granulosa and endothelial cells of primary and recurrent tumors.  VEGF expression was 
positively correlated to tumor microvessel density and to the expression of VEGFR2 at protein 
and mRNA level (13).  Also, high levels of VEGF were detected in the serum of patients with 
primary GCT, whose levels significantly dropped following tumor removal (13, 14).  
Together, these data demonstrate VEGF’s critical role in GCT disease that extends beyond 
affecting a single cell population, that is implicated in primary and recurrent disease, and that 
is in part responsible for tumor microvessel development.  This makes VEGF a logical 
therapeutic target for GCT. 
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Chapter 3: Transgenic mouse models 
 
3.1. Importance 
 Several mouse models genetically engineered to develop GCT have been created in an 
attempt to reproduce the human disease.  An animal model that is easily reproducible is 
especially useful for this disease as the incidence in women is quite low, which limits the 
possibility of organizing large-scale randomized trials.   Although the extent in which a mouse 
model is able to imitate the human disease is unclear (and varies depending on the given 
model), it serves as a powerful tool in which etiology, diagnosis, treatment, recurrence and 
especially novel therapeutic agents can be investigated.      
 
3.2. Existing models of GCT 
 
3.2.1. Inhibin #-subunit knockout 
Matzuk et al (64) created an inhibin #-subunit knockout model by using homologous 
recombination in mouse embryonic stem cells to delete the #-inhibin gene. Mice homozygous 
for the null allele (or inhibin-deficient) developed early onset (4 weeks), bilateral, multifocal, 
hemorrhagic, mixed or incompletely differentiated SCSTs with 100% penetrance in both sexes 
(6, 64).  Tumor development was accompanied by a cachexia-like wasting syndrome that 
ultimately led to their death (6, 93).  Based on these findings, #-inhibin was identified as a 
tumor-suppressor gene and inhibin, as a tumor-suppressor protein with gonadal specificity (64, 
93). 
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3.2.2. Targeted overexpression of luteinizing hormone 
Risma et al (94) generated a transgenic model with chronically elevated serum 
luteinizing hormone (LH) levels.  This model expressed a chimeric LH! subunit in 
gonadotropes that contained the C-terminal peptide of the human chorionic gonadotropin !-
subunit, linked to a bovine LH! subunit, and driven by a bovine #-subunit promoter (94).  The 
transgenic females showed chronically elevated LH levels (5-10 fold above controls), were 
infertile, and (some) developed pathologic ovarian lesions such as cyst formation, ovarian 
hypertrophy, and GCTs by 4-8 months of age (94).  The findings in this study suggested that 
gonadotropin hyperstimulation may be a mechanism for GCT tumorigenesis (94).  
 
3.2.3. Simian virus 40 T-antigen  
Kananen et al (95) produced transgenic mice that expressed the viral oncogene, simian 
virus 40 T-antigen, driven by a 6-kb fragment of the murine inhibin #-subunit promoter (6, 
96).  Transgenic females were infertile and developed ovarian granulosa and theca cells 
tumors by 5-7 months of age with 100% penetrance (6, 96).  Tumor growth was gonadotropin-
dependant, in a manner similar to inhibin-# knockout mice (95, 97). Mice displayed many 
similarities to the human disease, such as rapid development of primary tumors, continued 
folliculogenesis (until advanced disease), depressed serum gonadotropins, elevated serum 
inhibin levels, and similar histopathologic features and therefore represented a useful animal 
model for GCT (6, 97).   
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3.2.4. Estrogen receptor ! knockout 
Krege et al (98) generated transgenic mice lacking estrogen receptor ! (ER!-/-) by 
inserting a neomycin resistance gene into exon 3 of the coding gene by homologous 
recombination in embryonic stem cells.  ER!(-/-) female mice developed large ovarian sex 
cord (poorly differentiated) and GCTs (differentiated and estrogen secreting) with 100% 
penetrance by 2 years of age (6, 63).  Tumors had high proliferative indices and expressed 
high levels of nuclear phospho-SMAD3 and LH receptor (6, 63).  Fan et al (63) suggested that 
in the absence of ER!, the FSH/SMAD3 pathway is able to signal and in combination with 
increased ER# expression, induce proliferation, leading to the development of ovarian tumors 
(6).       
 
3.2.5. SMAD knockouts 
Pangas et al (99) developed a mouse model by genetic deletion of the bone 
morphogenetic protein (BMP) signaling transcription factors, SMADs 1, 5, and 8, specifically 
in ovarian granulosa cells (100).  Both female Smad1/5 double knockouts and Smad 1/5/8 
triple knockouts were infertile and developed poorly differentiated GCTs with 100% 
penetrance by 3 months of age (6, 99).  Almost 80% of mice developed peritoneal and 
lymphatic metastases (6, 99).  Further analyses of the Smad1/5 double knockout model 
showed similarities with the human juvenile-type GCT such as activation of TGF!/SMAD2/3 
pathway (6, 100).   These findings demonstrated a role for the SMAD family in the malignant 
transformation of granulosa cells, especially in juvenile form of GCT (99, 100).   
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3.2.6. Bone morphogenetic protein receptor knockouts 
Edson et al (101) generated BMP receptor 1A and 1B double-mutant mice that 
developed GCT.  Similar to SMAD1 and SMAD 5, which showed redundancy in suppressing 
GCT development in mice, BMPR1A and BMPR1B were found to act in conjunction to 
prevent GCT tumorigenesis (101).  This study in combination with the studies by Pangas and 
Middlebrook strongly suggest a role for the BMP pathway (including BMP receptors and 
SMADS) in ovarian tumor suppression (101).      
 
3.3. Transgenic GCT models relevant to the present study   
 
3.3.1. The Ctnnb1tm1Mmt/+; Amhr2tm3(cre)Bhr/+  model  
In 2005, Boerboom et al (52) reported that misregulated WNT/!-catenin signaling 
leads to ovarian GCT development.  !-catenin is a key effector of the WNT signal 
transduction pathway that is involved in cell proliferation and cell fate during embryogenesis, 
including embryonic development of the ovary (102-104).  Altered regulation of the WNT/!-
catenin pathway has previously been implicated in many types of cancer (52, 105, 106).   
Subsequently, a transgenic mouse model, Ctnnb1tm1Mmt/+; Amhr2tm3(cre)Bhr/+ (CA), was 
generated that expressed a dominant stable !-catenin mutant specifically in ovarian granulosa 
cells (Figure 3) (52).  By 6 weeks of age, CA mice developed pretumoral ovarian lesions 
resembling antral-size follicles, containing solid nests of disorganized and pleiomorphic 
granulosa cells, few proliferating cells, and no oocytes (52).  The lesions were highly 
vascularized (52).  In a subset of older mice, uni- and bilateral ovarian tumors consisting of 
large blood-filled cysts were discovered and revealed to be GCTs (52).  Discrete histological 
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patterns were found, the most common composed of a solid sheet of disorganized granulosa 
cells with randomly distributed, fenestrated, antrum-like spaces filled with eosinophilic 
material (52).  In a subset of tumors, well-organized areas of ossification and mineralization 
were found (52).  No dissemination beyond the ovaries was observed (52).  The prevalence of 
GCT increased over time with 0% of tumor formation in mice at 19 weeks of age, 44% at 6 
months of age, and 57% at 7.5 months of age, however, no increase in mortality rate was 
observed (52).  These findings suggested that constitutive activation of the WNT/!-catenin 
pathway in granulosa cells induces a premalignant state but requires additional factors to cause 
GCT formation (52,102).     
 
 
 
 
 
Figure 3 
 
WNT/!-catenin signaling pathway and dominant 
stable !-catenin mutant.  In the CA mouse model, 
GSK3! is unable to phosphorylate !-catenin 
(phosphorylation normally leads to degradation of 
!-catenin), which becomes a dominant stable 
mutant that translocates to the nucleus and mediates 
the transcription of target genes. APC = 
adenomatosis polyposis coli, DSH = disheveled, 
FZD = frizzled receptor, GSK3! = glycogen 
synthase kinase 3 beta, LRP = low-density 
lipoprotein receptor-related protein, TCF/LEF = 
transcription factor, T-cell specific/lymphoid 
enhancer factor 1.   
 
Adapted from Laguë, et al 2008. 
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3.3.2. The Ptentm1Hwu/tm1Hwu; Amhr2tm3(cre)Bhr/+ model  
Next, the possible involvement of the PI3K/AKT pathway in GCT development was 
investigated.  The PI3K/AKT pathway is known to contribute to the development of many 
cancer types when dysregulated, as many of its components are tumor-suppressor genes or 
proto-oncogenes (102, 107).  PTEN is a tumor suppressor gene that reduces PI3K/AKT 
activity by dephosphorylating phosphatidylinositol (3,4,5)-triphosphate and is inactivated in 
many types of cancer (102, 108).   
In 2008, a genetically engineered mouse model, Ptentm1Hwu/tm1Hwu; Amhr2tm3(cre)Bhr/+ 
(PA), was created by conditional targeting of PTEN, which triggered the derepression of the 
PI3K/AKT pathway in granulosa cells (Figure 4) (102).   In the PA model, only $7% of female 
mice developed aggressive, mostly bilateral, anaplastic GCTs with pulmonary metastases, 
diagnosed between 7 weeks to 7 months of age (102).  GCTs showed either a solid or 
trabecular pattern, with two distinct tumor cell populations (differing by degrees of anaplasia), 
areas of osseous metaplasia, and cystic structures (102).  These findings suggested that 
dysregulation of the PI3K/AKT pathway contributes to the pathogenesis of GCT and that the 
PA
 model provided the first metastatic phenotype in a transgenic mouse model of GCT (102).     
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3.3.3. The Ptentm1Hwu/tm1Hwu; Ctnnb1tm1Mmt/+; Amhr2tm3(cre)Bhr/+ model 
A mouse model was then generated to determine whether the WNT/!-catenin and 
PI3K/AKT pathways would interact in GCT development (102, 109-111).  In 
Pten
tm1Hwu/tm1Hwu; Ctnnb1tm1Mmt/+; Amhr2tm3(cre)Bhr/+ (PCA) mice, both PI3K/AKT and WNT/!-
catenin pathways were constitutively activated in granulosa cells and resulted in bilateral GCT 
development with 100% penetrance, perinatal onset, very rapid growth, and pulmonary tumor 
cell embolisms (by 6 weeks of age) (102, 112).  Abdominal distension due to large GCTs 
(>2cm in diameter) was severe by 7 weeks of age, typically causing death by 8 weeks of age 
(102, 112).  This phenotype resembled that of the PA mice, with solid and trabecular 
histological patterns, different cell populations, and areas of ossification (102).  In a surgical 
model of PCA, GCTs were surgically removed from 6 week-old mice that were later sacrificed 
6-16 weeks postoperatively (102, 112).  100% of mice showed large lung metastases (102).  In 
additional 6 week-old mice, tumors were removed and tumor cells suspended in saline were 
injected into the peritoneal cavity after closure of the abdominal wall (102).  6-9 weeks 
Figure 4 
PI3K/AKT pathway and conditional 
targeting of PTEN.  In the  PA mouse 
model, inactivated PTEN is unable to 
antagonize PI3K/AKT, which 
consequently remains active.  AC = adenyl 
cyclase, AKT = protein kinase B, FSH(R) 
= follicle stimulating hormone (receptor), 
IGR1(R) = insulin-like growth factor-1 
(receptor), PDK = 3-phosphoinositide-
dependent protein kinase, PI3K = 
phosphoinositide 3-kinase, PKA = protein 
kinase A, PTEN = phosphatase and tensin 
homolog, SFK = SRC family protein 
kinases.  
 
Adapted from Laguë, et al 2008. 
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postoperatively, the mice were sacrificed and multiple abdominal tumors invading the lungs, 
mesentery, peritoneum, abdominal muscles, pancreas, adrenal glands, and liver were 
discovered (102).  This surgical mouse model showed that PCA mice form pulmonary 
metastases and have the ability to seed into the peritoneal cavity in a manner similar to the 
advanced disease in women (17, 102).   
 
3.3.4. The KRASG12D; Ctnnb1tm1Mmt/+; Amhr2tm3(cre)Bhr/+ model 
In a collaborative laboratory, Richards et al (10) generated a mouse model in which 
constitutive activation of !-catenin was combined with oncogenic KRASG12D expression 
selectively in granulosa cells.  The RAS pathway is known to play important roles in normal 
ovarian function (113) including ovulation, oocyte maturation, and the terminal differentiation 
of granulosa cells (114-117).  Mutant KRASG12D has shown anti-proliferative properties, such 
as inhibition of proliferation, differentiation, and apoptosis in granulosa cells, which manifests 
as accumulations of small abnormal follicle-like structures in the ovary leading to premature 
ovarian failure (10, 118, 119).  Richards et al (10) generated a KRASG12D; Ctnnb1tm1Mmt/+; 
Amhr2
tm3(cre)Bhr/+ mutant model in which mice developed early-onset GCTs that displayed 
increased granulosa cell proliferation, decreased apoptosis, and impaired differentiation, which 
ultimately resulted in early death.  These unexpected observations resembled those found in 
the PCA model (10).  The authors concluded that either KRAS activation or PTEN loss is able 
to promote GCT progression if initiated by activated !-catenin (10).         
 
 
 
29 
!
3.3.5. Conclusions from the GCT models 
A synergistic interaction was found to occur between the PI3K/AKT and WNT/!-
catenin pathways that resulted in GCT development in all cases; however the molecular 
mechanisms mediating the interaction remain unknown (102).  The pretumoral ovarian lesions 
found in the CA model suggest that activation of the WNT/!-catenin pathway is involved in 
initiating GCT development (102).  In contrast, the rarity of GCT formation combined with 
the aggressive phenotype in the PA model suggest that the PI3K/AKT pathway is more 
involved in GCT progression (102).  Therefore, the development of GCTs with 100% 
penetrance obtained by combining the two pathways in the PCA model, might be explained by 
a coordinated effort by both pathways, with tumor growth initiated by one pathway (WNT/!-
catenin) followed by tumor progression stimulated by the other (PI3K/AKT) (102).  Also, the 
observed similarities in the PCA model compared to the advanced disease in women, such as 
formation of lung metastases and the ability to seed into the peritoneal cavity, suggest that 
similar molecular mechanisms of tumorigenesis might be involved (102, 112).   
 
Chapter 4: Targeting angiogenesis  
 
 Angiogenesis is known to play a crucial role in tumor growth and formation of 
metastases in a variety of cancer types (84, 120, 121).  For this reason, angiogenesis is a 
logical target for cancer treatment, and several agents that specifically inhibit one of the many 
steps of the angiogenic pathway have been generated (74, 79, 122-125).  Interest in novel 
therapies has also been prompted due to drug resistance and disease recurrence in association 
with chemotherapy in ovarian and other cancer types (76). Several classes of inhibitors that 
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target various steps of the VEGF pathway are currently under investigation and include 
VEGFR antibodies, soluble VEGFRs, aptamers, and small-molecule VEGFR tyrosine kinase 
inhibitors (TKI) (Figure 5) (74, 79, 84, 122-125).  However, the class of angiogenic inhibitors 
that has shown the most promise and is widely used in the clinical setting is monoclonal 
antibodies that bind and neutralize the VEGF ligand and consequently, prevent VEGF binding 
to its receptors (4, 80, 82, 123, 126, 127). 
 
 
 
 
 
Figure 5. Classes of VEGF inhibitors.  The VEGF pathway is inhibited by targeting either the 
VEGFA ligand or its main receptor VEGFR2.  Anti-VEGF antibodies, soluble VEGF receptors, 
and aptamers bind VEGFA and prevent binding to its main receptor VEGFR2.  Anti-VEGFR 
antibodies and small-molecule VEGFR TKIs bind VEGFR2 and prevent the transduction of 
intracellular signaling.  TKI = tyrosine kinase inhibitors.  
 
Adapted from Ferrara & Kerbel 2005. 
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4.1. Classes of angiogenic inhibitors  
 
4.1.1. VEGFR antibodies  
As VEGFR2 is the major receptor involved in transducing the VEGFA signaling 
cascade, its extracellular domain represents a logical target for the inhibition of tumor 
angiogenesis (79, 122).  Fully human monoclonal antibody, ramucirumab (IMC-1121B), is the 
most clinically advanced and specific inhibitor of VEGFR2 (74, 79).  Phase I and II trials have 
demonstrated its efficacy at causing tumor responses and stabilizing tumor size in patients 
with a variety of tumors who have received prior treatment, including treatment with other 
anti-angiogenic agents (79).  Many phase II and III trials are underway evaluating its efficacy 
in the treatment of melanoma, gastric, and ovarian cancer, among many others (79).   
 
4.1.2. Soluble VEGFRs 
Another approach to inhibiting VEGF signaling is to prevent VEGF from binding to its 
normal receptors by having it bind instead to decoy-soluble VEGFRs (123).  A potent high-
affinity VEGF blocker, aflibercept (or VEGF-Trap), is a decoy fusion protein consisting of 
domain 2 from VEGFR1 fused to domain 3 from VEGFR2 attached to the Fc fragment of 
IgG1, that binds and neutralizes all VEGFA isoforms (74, 79).  Aflibercept has been shown to 
inhibit tumor growth, suppress angiogenesis, induce tumor necrosis, and reduce tumor 
microvessel density in various in vitro and in vivo studies (79, 123, 128-131).  Although it 
hasn’t been approved for use in the clinical setting, it shows good potential, and many studies 
are currently underway evaluating its use in colorectal, lung cancer, and lymphoma (79, 131).     
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4.1.3. Aptamers 
RNA oligonucleotide ligands (or aptamers) to human VEGF165 potently inhibit VEGF 
binding to its receptors (124).  In the clinical setting, pegaptanib sodium (Macugen), is an 
aptamer that binds and blocks VEGF165 activity with high specificity and affinity, and was the 
first anti-VEGF agent to be approved by the FDA in 2004 for the treatment of neovascular 
age-related macular degeneration (124, 132). 
 
4.1.4. Small-molecule VEGFR tyrosine kinase inhibitors 
Small-molecule TKIs act by reversible competition with the ATP binding site of the 
catalytic (tyrosine) domain of several oncogenic tyrosine kinases, such as VEGFRs, and thus 
interfere with multiple signaling pathways (125).  A long list of inhibitors have shown efficacy 
in treating various forms of cancer.  Of particular interest, are the receptor TKIs that target 
VEGFRs, which include semaxinib (SU5416), vatalanib (PTK787/ZK222584), sorafenib 
(BAY 43-9006), sunitinib malate (Sutent, SU11248), cediranib (AZD2171), pazopanib 
(GW78603), and BIBF 1120, with sunitinib and sorafenib being the most established (84, 
125).  Sunitinib targets many tyrosine kinases including VEGFR, PDGFR, c-KIT, and FLT-3 
(133), and has shown improved progression-free survival and response rate in phase III trials 
of metastatic renal cell carcinoma (134).  This led to its FDA approval for treatment of 
advanced renal cell carcinoma as well as imatinib-resistant gastrointestinal stromal tumors 
(82).  Sorafenib targets Raf, VEGFR, EGFR, and PDGFR (135) and was shown to inhibit 
tumor cell proliferation and angiogenesis (125).  In a phase III trial, sorafenib improved 
progression-free survival and overall survival (82, 136) and was subsequently approved by the 
FDA for treatment of advanced/metastatic renal cell carcinoma and hepatocellular cancer (79).  
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Unfortunately, these two drugs demonstrated little activity and high toxicity in the treatment of 
ovarian cancer, so further development into its use in ovarian cancer was halted (76, 137, 
138).   
 
4.1.5. Monoclonal anti-VEGFA antibodies 
Bevacizumab (Avastin) is a recombinant humanized monoclonal IgG1 antibody (mAb) 
that binds and neutralizes all biologically active forms of VEGFA (74, 80) and was the first 
anti-angiogenic drug to be approved for cancer treatment (4).  Its activities include inhibiting 
neovascularization and inducing regression of existing microvessels, leading to inhibition of 
tumor growth and formation of metastasis (80, 126, 127).  Bevacizumab was investigated in 
two separate phase III trials in combination with chemotherapy for the treatment of metastatic 
colorectal cancer and advanced non-squamous, non-small-cell lung cancer (NSCLC) (139, 
140). Both studies showed significantly improved median survival, median duration of 
progression-free survival, and response rates (139, 140).  In 2004, the FDA approved the use 
of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer 
and NSCLC (11, 141, 142).  Today, bevacizumab is also approved for the treatment of 
metastatic kidney cancer in combination with interferon-#, and glioblastoma as second-line 
treatment (142).  
 
4.1.5.1. Dosage and administration 
 Several trials have attempted to establish an optimal bevacizumab dosage and schedule 
of administration however, no ideal dosing schemes exist that may be applied for all types of 
cancer (143, 144).  The effective and well tolerated dose of bevacizumab for the treatment of 
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metastatic colorectal cancer in combination with 5-fluorouracil (bolus-IFL) is 5mg/kg by 
intravenous (IV) injection every 2 weeks (143).  For the treatment of other tumor types, 
recommended doses vary between 5-15mg/kg every 2-3 weeks and are often combined with 
other chemotherapy drugs (145).  Although optimal dosing schemes vary, the same general 
guidelines for the administration of bevacizumab apply to all types of cancer (145).  For the 
first infusion, bevacizumab is administered slowly over 90 minutes to watch for signs of 
infusion reactions and is subsequently infused over a shorter period of time (30-60 minutes for 
subsequent infusions) as long as it is well tolerated (146).  Monitoring for signs of toxicity and 
adverse events (that are well described, see below) is necessary and if such signs occur, 
treatment is discontinued (146).   
 
4.1.5.2. In epithelial ovarian cancer 
More focus has been placed on investigating the use of bevacizumab in the treatment 
of the more common epithelial ovarian cancer than on GCT (11).  Phase II trials evaluating 
either single-agent bevacizumab or in combination with chemotherapy have shown improved 
response rates, median progression-free survival, and median overall survival relative to 
controls (147-152).  Recently, phase III trials have been conducted evaluating bevacizumab in 
combination with paclitaxel and carboplatin (in comparison to chemotherapy alone) and found 
significantly longer progression-free survival (153, 154).  Many other phase III trials of 
bevacizumab in combination with chemotherapy for the treatment of recurrent disease are 
currently underway (80).  Based on the encouraging results obtained in the treatment of 
epithelial ovarian tumors, bevacizumab has slowly begun to be incorporated into treatment 
protocols for GCT. 
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4.1.5.3. In GCT 
To date, very few studies have investigated the use of bevacizumab in the treatment of 
GCT and the results have yielded little insight (11, 15, 16).  Tao et al (11) evaluated the 
clinical efficacy of bevacizumab with or without chemotherapy and found a response rate of 
38% and a clinical benefit rate of 63%.  It must be noted that this study was limited by its 
retrospective nature, its small sample size, and the variation of treatments administered (11).  
In a case report documented by Kesterson et al (15), a patient with refractory GCT was treated 
with paclitaxel and bevacizumab. A symptomatic improvement of the patient’s malignant 
ascites was obtained and attributed to bevacizumab (as prior monotherapy with paclitaxel 
offered no improvement (15).  Conversely, a case report documented by Barrena et al (16) 
found no clinical improvement with bevacizumab therapy in the first-line treatment of adult-
type GCT.  It is therefore difficult to draw any conclusions from the limited number of small-
scale studies evaluating bevacizumab for the treatment of GCT.  If standardized treatment 
regimens incorporating bevacizumab are to be established, then large-scale randomized trials 
are required.   
 
4.2. Resistance  
Although inhibitors of the VEGF pathway are valid treatment options that have shown 
promising results in the treatment of various cancer types, their benefits can be transitory (84, 
155).  Many theories have attempted to explain this acquired resistance to anti-angiogenic 
drugs, some of which include: VEGFA replacement by other angiogenic pathways, the 
selection of aggressive tumor cells that are resistant to hypoxia and are less dependent on 
angiogenesis, and vascular remodelling and stabilization that is less responsive to angiogenic 
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inhibition (4, 84, 156-158).  Beyond having a transitory effect, some VEGF inhibitors have 
even been implicated in accelerating tumor progression and worsening patient prognosis.  In a 
study by Ebos et al (155), short-term treatment with sunitinib was found to accelerate 
metastatic tumor growth and decrease overall survival in a mouse model.  Similarly, Pàez-
Ribes et al (159) observed increased invasiveness and metastasis after treatment with a 
VEGFR2 inhibitor in mouse models of pancreatic neuroendocrine carcinoma and 
glioblastoma.  These findings suggest that targeting the VEGF signaling pathway is effective 
in the short-term (e.g. at reducing tumor burden), but in the long-term, the tumor develops a 
resistance to treatment, disseminates, and forms metastases (159).   
 
4.3. Adverse events  
Although bevacizumab is generally well tolerated, monotherapy with this agent has 
been associated with a number of side effects, with gastro-intestinal perforation (11.4%), 
hypertension (9.1-9.7%), proteinuria (1.6-15.9%), and arterial thromboembolisms (1.6-6.8%) 
occurring most often (147-149). Other adverse events that have been reported include: 
hematologic, gastro-intestinal, allergic, hepatic, pain, bleeding, dyspnea, pulmonary emboli, 
and impaired wound-healing (147-149).  In a meta-analysis including 16 randomized control 
trials and a total of 10,217 patients diagnosed with various advanced solid tumors, the overall 
incidence of fatal adverse events with bevacizumab was 2.5%, with the most common causes 
being hemorrhage (23.5%), neutropenia (12.2%), and gastrointestinal tract perforation (7.1%) 
(80, 160).  These side effects and the development of resistance found with some VEGF 
inhibitors are critical factors that must be taken into consideration when evaluating anti-
VEGFA therapy in future trials. 
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4.4. Combinatorial therapies  
Given the complexity of signaling pathways involved in carcinogenesis, targeting a 
single pathway has shown limited clinical benefits.  For this reason, combining different 
treatment modalities that target different pathways tends to be a more effective approach (16).  
Preclinical studies have shown synergistic effects in suppressing tumor growth by combining 
anti-angiogenic drugs with chemotherapy or radiation therapy (121); however the mechanisms 
of action remain theoretical.  Browder et al (161) and Klement et al (162) suggest that 
metronomic chemotherapy preferentially damages endothelial tumor cells and by 
simultaneously blocking VEGFA, endothelial cell survival signal is reduced, which further 
amplifies endothelial cell targeting by chemotherapy, and consequently, more cancer cells are 
killed (84).  Another hypothesis, by Jain et al (163) suggests that anti-angiogenic agents 
normalize the tumor vasculature and as a result, excessive endothelial and perivascular cells 
are pruned, tumor hypoxia and interstitial pressure in tumors are reduced, leading to improved 
oxygenation, perfusion, and delivery of chemotherapy (82, 84, 87, 164).    
  
38 
!
Hypothesis and objectives 
Few studies have focused on investigating adjuvant treatment protocols for GCT in 
women as the prevalence is quite low and consequently, large-scale randomized trials are 
difficult to perform.  However, GCTs still represent up to 5% of all ovarian tumors, are 
potentially malignant with a tendency toward late recurrence, require surveillance for life, and 
are therefore of clinical importance.  Taking into consideration the role of angiogenesis and 
VEGF in GCT disease, we hypothesized that the VEGFA signaling pathway is a valid and 
useful pharmacological target for the treatment of GCT.  We proposed that the PCA model 
would be a useful preclinical model for the investigation of this therapeutic approach, as it 
imitates the advanced disease in women, with early onset and 100% penetrance.  
 In order to test this hypothesis, this study’s objectives were to evaluate the effect of 
anti-VEGFA antibody in the PCA model on: 
1. Tumor growth and survival  
2. Cell proliferation and apoptosis  
3. Tumor microvessel density 
4. Activation of VEGFR2 signaling pathway effectors    
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ABSTRACT 
 
Although angiogenesis has been proposed as a therapeutic target for the treatment of 
ovarian granulosa cell tumor (GCT), its potential has not been evaluated in controlled studies.  
To do so, we used the Ptentm1Hwu/tm1Hwu;Ctnnb1tm1Mmt/+;Amhr2tm3(cre)Bhr/+ (PCA) mouse model, 
which develops GCTs that mimic the advanced disease in women.  A monoclonal anti-
vascular endothelial growth factor A (VEGFA) antibody was administered weekly to PCA 
mice beginning at 3 weeks of age.  By 6 weeks of age, anti-VEGFA therapy significantly 
decreased tumor weights relative to controls (P<0.05) and increased survival, with all treated 
animals but none of the controls surviving to 8 weeks of age.  Analyses of PCA tumors 
showed that anti-VEGFA treatment resulted in significant decreases in tumor cell proliferation 
and microvessel density relative to controls (P<0.05).  However, treatment did not have a 
significant effect on apoptosis or tumor necrosis.  The VEGFA receptor 2 (VEGFR2) 
signaling effector p44/p42 MAPK, whose activity is associated with cell proliferation, was 
significantly less phosphorylated (i.e. activated) in tumors from the treated group (P<0.05).  
Conversely, no significant difference was found in the activation of AKT, a VEGFR2 
signaling effector associated with cell survival.  Together, these results suggest that anti-
VEGFA therapy is effective at inhibiting GCT growth in the PCA model, and acts by reducing 
microvascular density and cell proliferation via inhibition of the VEGFR2-MAPK pathway.   
Findings from this preclinical model therefore support the investigation of targeting VEGFA 
for the adjuvant treatment of GCT in women. 
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INTRODUCTION 
 
The granulosa cell tumor (GCT) is the most prevalent of the sex cord/stromal subgroup 
of ovarian tumors in women, and is thought to represent up to 5% of all ovarian cancers [1-4].  
Although GCT is often characterized as a low-grade malignancy [5, 6], approximately 80% of 
patients with stage III or IV tumors die from recurrent disease [7].  Furthermore, a large 
proportion of patients develop recurrences as late as 40 years after the initial diagnosis and 
treatment [8], and therefore, fastidious long-term follow-up is required [1, 3, 9].  Despite the 
importance and insidiousness of GCT, it has received very little attention from the cancer 
research community, particularly relative to the more prevalent epithelial ovarian tumors.  
Perhaps as a consequence of this, the development of therapeutic approaches for GCT has 
lagged well behind other forms of ovarian cancer.  Initial management of GCTs involves 
cytoreductive surgery, and in cases of recurrence or advanced disease, adjuvant treatment is 
frequently attempted [1, 3-5, 9, 10].  These adjuvant treatments have included chemotherapy, 
radiotherapy, hormonal therapy, and more recently, anti-angiogenic therapy [1, 3, 4, 9, 10].  
Studies aiming to evaluate current adjuvant treatment protocols for GCTs in women have been 
limited to retrospective studies and case reports, and no well-designed randomized studies 
have been conducted to determine if any such regimen actually confers a survival advantage 
[4, 5, 11-13].   
Among the potential therapeutic targets that have been proposed for the development of novel 
treatments for GCT [14-16], angiogenesis would appear to be particularly promising.  GCTs 
are highly vascularized tumors, and angiogenesis is suspected to play an important role in their 
development and progression [4, 17, 18].  Vascular endothelial growth factor A (VEGFA) is a 
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key mediator of angiogenesis and is implicated in endothelial cell proliferation, migration, 
survival and vascular permeability [18-21].  VEGFA is overexpressed in 94% of GCTs [2] and 
its main receptor, VEGFR2, is expressed at high levels in 82% of primary and recurrent GCTs 
in both endothelial and granulosa cells [18].  VEGF was shown to be produced by endothelial 
as well as granulosa tumor cells [17].  In addition, VEGFA also has well-established pro-
proliferative and cytoprotective functions in normal granulosa cells [22-24], and could 
therefore serve to promote GCT cell proliferation and suppress apoptosis, in addition to 
promoting angiogenesis.  Collectively, these data suggest a very strong potential for VEGFA 
as a therapeutic target for GCT. 
Avastin® (bevacizumab) is a recombinant humanized monoclonal anti-VEGFA 
antibody that has received FDA approval for use in the treatment of metastatic colorectal 
cancer and non-squamous, non-small-cell lung cancer in combination with chemotherapy [4, 
25-27], as well as metastatic renal cell carcinoma (combined with interferon alpha) and 
glioblastoma (as a second-line treatment) [http://www.avastin.com/patient/index.html 
(Accessed May 30, 2012)].  Whereas some reports have shown potential beneficial effects of 
bevacizumab in the treatment of epithelial ovarian cancer [28-30], very few studies have 
investigated its use in the treatment of GCT.  Tao et al [4] carried out a small retrospective 
case series and evaluated the clinical efficacy of bevacizumab with or without concurrent 
chemotherapy and found a response rate of 38% and a clinical benefit rate of 63%.  This study 
was limited, however, by its retrospective nature, its small sample size, and the variation of 
treatments administered [4].  One case report [31] reports symptomatic improvement with 
bevacizumab combined with paclitaxel for the treatment of refractory GCT while another case 
report [32] found no clinical improvement with bevacizumab for the first-line treatment of 
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adult-type GCT.  No prospective trial has been conducted to determine the efficacy of single-
agent bevacizumab in the treatment of GCT.      
A major factor that has impeded the development of novel therapeutic approaches for 
ovarian cancer (including GCT) has been the dearth of relevant preclinical animal models [10, 
33, 34].  We have recently developed a genetically engineered mouse model, 
Pten
tm1Hwu/tm1Hwu;Ctnnb1tm1Mmt/+;Amhr2tm3(cre)Bhr/+ (PCA), in which the PI3K/AKT is 
derepressed and the WNT/CTNNB1 pathway is constitutively activated specifically in 
granulosa cells [35].  PCA mice develop bilateral GCTs with 100% penetrance, peri-natal 
onset, rapid growth, and many histopathologic features of the human disease [35, 36].  
Importantly, as for the advanced disease in women, PCA GCTs can form distant metastases 
and disseminate within the peritoneal cavity [35, 36].  In this study, we therefore used the PCA 
preclinical model to perform the first controlled study to investigate the efficacy of anti-
VEGFA therapy for the treatment of GCT disease.  We hypothesized that intra-peritoneal 
administration of anti-VEGFA antibody would effectively reduce tumor growth, reduce tumor 
vasculature and increase tumor cell apoptosis, thereby improving survival in this murine 
model of GCT.   
 
MATERIALS AND METHODS 
 
Animals and treatments  
Pten
tm1Hwu/tm1Hwu;Ctnnb1tm1Mmt/+;Amhr2tm3(cre)Bhr/+ (PCA) mice were obtained by 
selective breeding of the Ptentm1Hwu, Ctnnb1tm1Mmt, and Amhr2tm3(cre)Bhr parental strains, and 
genotypes were verified as previously described [35].  Tumor development in the PCA model 
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follows a predictable course.  At birth, all PCA mice display nests of dysplastic cells in both 
ovaries.  Tumors are macroscopically apparent at 3 weeks of age, and grow in a very rapid and 
aggressive fashion with abdominal distension becoming apparent by 5 weeks of age and 
extreme by 7 weeks.  Death due to tumor-related causes inevitably occurs before 9 weeks of 
age [35, 36].  PCA mice were administered anti-mouse VEGFA monoclonal antibody clone 
B20-4.1.1 (provided by Genentech, Inc., San Francisco, CA) by intraperitoneal (IP) injection 
at 5mg/kg (or 0.9% NaCl as a control) once a week beginning at 3 weeks of age.  The mice 
were sacrificed at 3, 4, 5, 6, 7 and 8 weeks of age and their ovarian tumors, lungs and 
abdominal organs were collected for subsequent use in immunohistochemistry, 
immunofluorescence, TUNEL assays, Western blot analysis and histopathology.  In order to 
evaluate the effects of variable doses, additional PCA mice received 2.5, 5, or 10 mg/kg of 
anti-VEGFA antibody weekly IP beginning at 3 weeks of age until 6 weeks of age, at which 
point mice were sacrificed and their tumors and organs were collected as described above (n= 
8-16 mice/treatment/timepoint).  Masses of tumors used in all analyses are indicated in 
Supplemental Table 1. 
 All animal procedures were approved by the Institutional Animal Care and Use 
Committee of the University of Montreal and conformed to the Canadian Council on Animal 
Care Policy on Humane Care and Use of Laboratory Animals. 
 
Immunohistochemistry and Immunofluorescence 
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded, 3 µm 
ovarian tumor sections (n = 4 mice/treatment/timepoint) using the VectaStain Elite Avidin-
Biotin Complex Kit (Vector Laboratories, Inc., Burlingame, CA) as directed by the 
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manufacturer.  Sections were probed with Proliferating Cell Nuclear Antigen (PCNA) mouse 
monoclonal antibody (Cell Signaling Technology, Danvers, MA, catalog number 2586) as 
directed by the manufacturer, except incubation with the primary antibody (dilution 1:2000) 
was performed for 30 minutes, and incubation with the secondary antibody (biotinylated anti-
mouse reagent, Vector Laboratories, Inc., dilution 1:250) was done for 10 minutes.  Sections 
were also probed with phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XPTM 
rabbit mAb (Cell Signaling Technology, catalog number 4370, dilution 1:200) as directed by 
the manufacturer.  Staining was done using 3,3’-diaminobenzidine peroxidase substrate kit 
(Vector Laboratories, Inc.) as directed by the manufacturer.  In order to determine the number 
of PCNA-positive cells, 4 fields per tumor (1 or 2 tumors per animal; at a 630x magnification) 
were selected at random.  From each field, cells were counted within a randomly-selected 
circular area with a 90 µm diameter.  For each tumor, % of PCNA-positive cells was 
calculated by dividing the sum of PCNA-positive cells (from all fields) by the total number of 
cells. Sections of the same tumors stained with HPS were also evaluated to quantify mitotic 
figures per 400x field as a second measure of cell proliferative activity, as well as to estimate 
the extent of tumor necrosis.  The area of coagulative necrosis (characterized by increased 
eosinophilia and glassy appearance of the area with loss of cellular details) was evaluated by 
light microscopy and was estimated for each tumor as a percentage of the total tumor cross 
section area.  All slides were evaluated by a board-certified veterinary pathologist who was 
blinded with regard to the treatment received.  
Immunofluorescence was performed on O.C.T.-embedded (Sakura Finetek U.S.A., Inc. 
Torrance, CA) frozen ovarian tumors (n = 4 mice/treatment/timepoint). Samples were stored at 
-80oC until they were sectioned (4 µm) and allowed to dry for 5 hours.  The slides were quick-
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fixed with 100% acetone (-20oC) for 20 seconds, wrapped in aluminum foil and stored at -
80oC.  When ready, the slides were thawed at room temperature for 20 minutes, fixed with 
100% acetone (-20oC) for 10 minutes, followed by 70% ethanol (-20oC) for 5 minutes.  The 
slides were blocked with 10% goat serum diluted in PBS for 30 minutes and then probed with 
rat anti-mouse CD31 antibody (BD Biosciences, Franklin Lakes, NJ, catalog number 558736, 
dilution 1:300, overnight at 4oC) and/or fluorescein-labeled Lycopersicon Esculentum 
(Tomato) Lectin (Vector Laboratories, Inc. catalog number FL-1171, dilution 1:1000, 10 
minutes at RT) diluted in 3% goat serum in PBS.  The CD31-probed slides were incubated 
with the secondary antibody Alexa Fluor 594 goat anti-rat IgG (Invitrogen, Burlington, ON, 
catalog number A11007, dilution 1:2000) for 1 hour at room temperature, diluted in 3% goat 
serum.  The slides were washed with 1% Triton-X-100 (Bioshop Canada, Inc., Burlington, 
ON) in PBS for 10 minutes and mounted with Vectashield mounting medium for fluorescence 
with DAPI (Vector Laboratories, Inc.).  In order to evaluate the amount of CD31 signal, 5 
fields per tumor (at 200x magnification) were selected at random and ImageJ software was 
used to quantify the area of signal emitted in each field. The evaluator was blinded with 
respect to the ages and treatments received.  The double-labeled (CD31 + lectin) slides were 
used to confirm the specificity of endothelial cell staining.  
 
TUNEL assays 
TUNEL assays were performed on formalin-fixed, paraffin-embedded, 3 µm ovarian 
tumor sections (n = 4 mice/treatment/timepoint) using the In Situ Cell Death Detection Kit, 
TMR red (Roche Diagnostics GmbH, Mannheim, Germany, catalog number 12156792910), 
according to the manufacturer’s instructions.  Vectashield mounting medium for fluorescence 
47 
!
with DAPI (Vector Laboratories, Inc.) was used to mount the slides.  In order to determine the 
number of positive cells for TUNEL, 4 fields per tumor (1 or 2 tumors per animal; at 630x 
magnification) were selected at random.  Within each field, a circular area with a 90 µm 
diameter was chosen at random in order to count the number of TUNEL-positive cells.  For 
each tumor, % TUNEL-positive cells was calculated by dividing the sum of TUNEL-positive 
cells (from all fields) by the total number of cells.  A normal healthy ovary containing atretic 
follicles was used as a positive control. The evaluator was blinded with respect to the ages and 
treatments received.   
 
Western Blot Analysis 
Tumor samples from 6 week-old PCA mice were used for Western blot analysis (n = 4 
mice/treatment).  Protein extracts were obtained using T-PER Tissue Protein Extraction 
Reagent and Halt Protease and Phosphatase Inhibitor Single-Use Cocktail (Thermo Fisher 
Scientific, Rockford, IL, catalog numbers 78510 and 78442, respectively) as described by the 
manufacturer.  Protein concentrations were quantified using the Bradford method.  Samples 
(25µg or 50µg) were resolved on 7-12% sodium dodecyl sulfate-polyacrylamide gels and 
transferred to Hybond-P PVDF Membrane (GE Amersham, Piscataway, NJ).  Blots were 
probed with primary antibodies against p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb, 
phospho-p44/42 MAPK (Erk 1/2) (Thr202/Tyr204) (D13.14.4E) XPTM Rabbit mAb, AKT, 
phospho-AKT (Ser473) (587F11) Mouse mAb, VEGF receptor 2 (55B11) Rabbit mAb, 
phospho-VEGF receptor 2 (Tyr951) (15D2) Rabbit mAb, phospho-VEGF receptor 2 (Tyr 
1059) (D5A6) Rabbit mAb (Cell Signaling Technology, catalog numbers 4695, 4370, 9272, 
4051, 2479, 4991 and 3817 respectively), and !-Actin (C4) (Santa Cruz Biotechnology, Inc., 
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Santa Cruz, CA, catalog number sc-47778) as directed by the manufacturers.  The blots were 
incubated with ECL Peroxidase-labeled secondary antibodies (GE Amersham) and then ECL 
Plus Western blotting detection reagents (GE Amersham) were used to visualize the protein 
bands by chemiluminescence on High-Performance Chemiluminescence Film (GE 
Amersham).  The signal strengths were quantified using Kodak 1D v.3.6.5 software (Eastman 
Kodak Company). 
 
Statistical methods 
 Effects of antibody treatment on tumor size, cell proliferation, cell apoptosis, CD31 
signal intensity and VEGFA signaling pathway protein expression were analyzed by ANOVA, 
followed by Newman-Keul’s or Dunnett’s post-test to identify differences between specific 
groups.  P<0.05 was considered statistically significant.  Prism 4.0a software (GraphPad 
Software, Inc., San Diego, CA) was used for analysis.   
 
RESULTS 
 
Anti-VEGFA therapy reduces tumor burden and improves survival in PCA mice 
To study the efficacy of anti-VEGFA therapy in the PCA model, mice were treated 
with anti-VEGFA antibody (5mg/kg, IP) once a week beginning at 3 weeks of age.  The mice 
were sacrificed at 3, 4, 5, 6, 7 and 8 weeks of age and their ovarian tumors and viscera were 
collected for analysis.  A dose-response experiment was also conducted using 2.5, 5 and 10 
mg/kg of anti-VEGFA, IP, once a week, beginning at 3 weeks of age until 6 weeks of age, at 
which point the mice were sacrificed.    
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 PCA mice treated with anti-VEGFA antibody in the dose-response trial demonstrated 
that significant effects on tumor burden were obtained at the 5mg/kg dose, but no further 
benefit was obtained at 10mg/kg (Fig. 1A).  In the timecourse trial, PCA mice showed 
significantly reduced ovarian tumor weights at 6 and 7 weeks of age relative to controls (Fig. 
1B).  Importantly, anti-VEGFA treatment also extended the survival of treated animals.  
Whereas all animals treated with anti-VEGFA antibody survived up to 8 weeks of age, 27,8% 
(n= 5 of 18) of controls died before 7 weeks of age or had to be euthanized due to 
deteriorating health, and no control mice survived until 8 weeks of age (Fig. 1C).  
  
Anti-VEGFA treatment reduces cell proliferation but does not affect apoptosis in PCA 
GCTs 
To determine the cause(s) of reduced GCT size in anti-VEGFA-treated PCA mice, cell 
proliferation was assessed by PCNA immunohistochemistry and by histological analysis of 
mitotic figures.  A significant decrease in the number of PCNA-positive cells was observed in 
the anti-VEGFA treated group compared to the saline group at 6 weeks of age (Fig. 2A).  
Likewise, fewer mitoses per high-power field were observed at 6 weeks of age in the anti-
VEGFA treated group (Figure 2B).  
TUNEL assays were performed to determine if increased tumor cell apoptosis 
contributed to the decrease in tumor growth in anti-VEGFA-treated mice.  No significant 
difference in the number of TUNEL-positive cells in the anti-VEGFA-treated group compared 
to the saline group was observed at any age (Fig. 3A).  Likewise, although small foci of 
necrosis were observed in some tumors (particularly at 6 weeks), anti-VEGFA therapy did not 
increase the overall area of necrosis observed in histological sections (Fig. 3B). 
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Anti-VEGFA treatment significantly reduces tumor microvessel density in GCTs 
To study the effects of anti-VEGFA antibody on angiogenesis in PCA GCTs, the tumor 
microvasculature was visualized by immunofluorescence using the endothelial cell marker 
CD31 (PECAM-1).  Tumors from 6 week-old, anti-VEGFA-treated mice had a markedly 
lower microvessel abundance than saline-treated controls, with CD31 signal reduced by more 
than half in the 5mg/kg group (Fig. 4A-C).  Specificity of the CD31 signal for endothelial cells 
was confirmed by double-labeling with tomato plant lectin (Fig. 4D).      
 
Intracellular signaling is altered in tumors from PCA mice treated with anti-VEGFA 
antibody 
To identify potential alterations in intracellular signaling activity downstream of VEGF 
receptor 2 (VEGFR2) caused by anti-VEGFA treatment, activity levels of the p44/42 MAPK 
(ERK1/2) and the PI3K/AKT signaling pathways were evaluated by western blotting.  Levels 
of phospho-p44/42 MAPK (Thr202/Tyr204) were significantly lower in GCTs from 6 week-
old PCA mice that had received as little as 2.5mg/kg of anti-VEGFA antibody, as was the ratio 
of phosphorylated-to-total p44/42 MAPK (Fig. 5A, B), indicative of decreased MAPK 
signaling activity.  Immunohistochemistry was performed to determine the cell population(s) 
within the tumors in which this decrease occurred, which showed that granulosa, stromal and 
endothelial cells (identified based on morphological characteristics) all appeared to be affected 
(Figure 5C).   
Contrary to the MAPK pathway, no significant difference was found in the expression 
of AKT or phospho-AKT between the various anti-VEGFA-treated groups and the saline 
group (Figure 6A, B), suggesting that activity of the PI3K/AKT pathway was not altered by 
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treatment.  Activation of VEGFR2 was also studied, but tyrosine phosphorylation of the 
receptor at sites 951 and 1059 could not be detected in either the anti-VEGFA treated or the 
control groups (not shown).   
 
DISCUSSION 
  
Few therapeutic options exist for advanced-stage and recurrent GCT, and none of the 
widely-used chemotherapeutic regimens has been rigorously evaluated with regards to its 
effectiveness [11, 13, 37, 38].  The development of validated adjuvant chemotherapies for 
GCT is therefore of paramount importance.  Whereas angiogenesis (i.e., VEGFA) been 
proposed as a therapeutic target for GCT [4, 17, 18, 31, 32], clinical investigations of anti-
VEGFA therapies have so far been limited to small-scale retrospective studies and case 
reports, and have yielded limited insight [4, 31, 32].  In this report, we used the recently-
developed PCA mouse model, which develops an ovarian cancer that mimics many of the 
histological and biological aspects of advanced human GCT [35, 36], to investigate the 
efficacy of an anti-VEGFA antibody analogous to bevacizumab.  Our results in this preclinical 
model clearly show that anti-VEGFA therapy extends survival and significantly slows tumor 
growth.  These findings therefore support the prospective investigation of anti-VEGFA 
therapy for the adjuvant treatment of GCT in women. 
 Our findings indicate that the main mechanism by which the anti-VEGFA antibody 
slowed tumor growth was inhibition of tumor cell proliferation, rather than induction of 
apoptosis.  Proliferation was presumably inhibited, at least in part, by reduced microvessel 
density, resulting in decreased delivery of nutrients and growth factors to tumor cells.  
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However, our results also suggest that the anti-VEGFA therapy may have acted directly upon 
the tumor cells themselves to inhibit proliferation.  Indeed, apparent lower levels of 
phosphorylation (i.e., activity) of the VEGFA receptor signaling effector MAPK were 
observed not only in endothelial cells but also in tumor cells from anti-VEGFA-treated mice.  
As MAPK signaling is thought to mediate the pro-proliferative actions of VEGFA [39, 40], 
this suggests that the anti-VEGFA treatment acted to sequester pro-proliferative VEGFA from 
the tumor cells in the PCA model.  This would be entirely consistent with the well-established 
role of VEGFA as a granulosa cell growth factor in the context of normal ovarian follicle 
development [41, 42], and would indicate that GCT cells retain a certain dependence on 
VEGFA as a proliferative signal even after oncogenic transformation.  VEGFA also signals 
via the PI3K/AKT pathway, whose activity is associated with the anti-apoptotic effects of 
VEGFA [43, 44].  Anti-VEGFA therapy had no effect on tumor cell apoptosis in the PCA 
model, and did not alter AKT phosphorylation (i.e., activity).  VEGFA/AKT cytoprotective 
signaling would therefore not appear to be relevant to the pathogenesis of GCT, at least in the 
PCA model. 
 The effect of the anti-VEGFA antibody on GCT microvessel density in the PCA model 
concurs with findings from other studies that evaluated the effect of analogous anti-VEGFA 
antibodies on vascular growth.  Korsisaari et al [27] found a significant reduction in vessel 
density after 3 weeks of administration of anti-VEGFA mAb G6-31 in a murine model of 
intestinal adenoma.  Likewise, Borgström et al [45] found complete inhibition of angiogenesis 
in micro tumors with administration of anti-VEGF antibody A4.6.1 in a tumor xenograft study 
of human prostate carcinoma.  In past studies, anti-VEGFA therapy has been found to reduce 
tumor microvessel density, decrease permeability, increase tumor pericyte coverage and 
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stabilize the basement membrane, which all contribute to forming a more normalized tumor 
vasculature [46, 47].  In consequence, tumor hypoxia and interstitial fluid pressure are 
reduced, which allows improved delivery of chemotherapy to the tumor, as observed in 
clinical trials [19, 47, 48].  If this holds true for GCT as well, another benefit of anti-VEGFA 
therapy may be to enhance the effects of other chemotherapeutic agents when used in the 
context of combinatorial therapy.  The PCA mouse model may prove useful to test this 
hypothesis, as well as for the subsequent development of combinatorial treatment schemes. 
  In summary, this study shows that monotherapy with anti-VEGFA antibody is 
effective at suppressing tumor growth and extending survival in the PCA model of GCT.  
Targeting VEGFA reduced tumor cell proliferation and microvascular density, which could 
sensitize GCTs to the effects of other chemotherapeutic agents.  Based on our results, we 
conclude that anti-VEGFA therapy shows great potential in the adjuvant treatment of GCT.  
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FIGURE LEGENDS 
 
Figure 1. Anti-VEGFA antibody reduces tumor burden and improves survival of PCA mice 
with GCTs. A, Effects of different doses of anti-VEGFA on tumor mass in 6 week-old PCA 
mice (n= 8-16 mice/treatment/time).  Data are shown as means (columns) ± SEM (error bars).   
Significant difference from control (saline) is indicated with one (*: P < 0.05) or two asterisks 
(**: P < 0.01).  Photographs of representative tumors are shown below the graph.  B, 
Timecourse of GCT mass with or without weekly anti-VEGFA treatment in PCA mice (n=10-
26 mice/treatment/time). C, Survival curves indicating the proportion of experimental mice 
surviving at the indicated times (n= 4-18 mice/treatment/time).  Anti-VEGFA-treated mice 
were sacrificed for humane reasons at 3 days past the 8 week timepoint. 
 
Figure 2. Anti-VEGFA antibody reduces cell proliferation in GCTs from PCA mice. A, Graph 
depicting the proportion (as %) of PCNA-positive cells in PCA mice administered anti-
VEGFA antibody or saline (control), n = 4 mice/treatment/timepoint. Representative 
photomicrographs of PCNA-stained tumors are shown below the graph at a 630x 
magnification.  B, Evaluation of mitotic indices in the tumors described in panel A.  Error bars 
= SEM.  Significant difference from control (P < 0.05) is indicated with an asterisk (*). 
 
Figure 3. Anti-VEGFA antibody has no significant effect on apoptosis or tumor necrosis in 
GCTs from PCA mice. A, Graph depicting the proportion (as %) of TUNEL-positive cells in 
PCA mice administered anti-VEGFA antibody or saline (control), n = 4 
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mice/treatment/timepoint.  B, Evaluation of extent of tumor necrosis (as % of total surface in 
histological sections) in the tumors described in panel A. Error bars = SEM. 
 
Figure 4.  Anti-VEGFA antibody significantly reduces microvessel density in GCTs from 6 
week-old PCA mice. A, Graph depicting CD31 immunofluorescence signal strengths in GCTs 
from 6 week-old PCA mice that received the indicated treatments (n = 4 animals/treatment). 
Data are shown as means (columns) ± SEM (error bars).  Significant difference from control 
(saline) is indicated with one (*: P < 0.05) or two asterisks (**: P < 0.01). B, Representative 
photomicrograph (200x magnification) depicting CD31 fluorescent signal in the GCT of a 6 
week-old PCA mouse.  CD31-specific signal is red, nuclei are counterstained with DAPI 
(blue). C, As per panel B, showing a tumor from an anti-VEGFA treated mouse.  D, As per 
panel B, except endothelial cells were labeled with tomato plant lectin (green) in addition to 
CD31 immunolabeling; 630x magnification.  Overlap in lectin and CD31 signals appears 
yellow, and confirms the specific labeling of endothelial cells by CD31. 
 
Figure 5. Anti-VEGFA antibody significantly reduces MAPK activation in GCTs from 6 
week-old PCA mice.  A, Graph depicting expression of MAPK, phospho-MAPK and 
phospho-MAPK:total MAPK ratio in tumors from 6 week-old PCA mice that received the 
indicated treatments.  Data are densitometric quantification of signals obtained by western 
blotting (n=4 per treatment). Data are shown as means (columns) ± SEM (error bars).  
Significant difference from control (saline) is indicated with one (*: P < 0.05) or two asterisks 
(**: P < 0.01).  B, Representative western blot images from the analyses shown in A (n = 2 
samples/treatment).  !-Actin was used as a loading control.  C, Immunohistochemical analysis 
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of phospho-MAPK expression in tumors from 6 week-old PCA mice treated with anti-VEGFA 
(5mg/kg) or saline control; 400x magnification. 
 
Figure 6. Anti-VEGFA antibody has no significant effect on AKT activation in GCTs from 6 
week-old PCA mice. A, Graph depicting expression of AKT, phospho-AKT and phospho-
AKT:total AKT ratio in tumors from 6 week-old PCA mice that received the indicated 
treatments.  Data are densitometric quantification of signals obtained by western blotting (n=4 
per treatment).  Data are shown as means (columns) ± SEM (error bars).  B, Representative 
western blot images from the analyses shown in A (n = 2 samples/treatment).  !-Actin was 
used as a loading control.  
 
SUPPLEMENTARY MATERIAL 
Supplemental Table 1.  Masses of granulosa cell tumors used for A, immunohistochemistry, 
mitotic figures, TUNEL assay, % necrosis. B, Tumors from 6 week-old mice used for 
immunofluorescence. C, Tumors from 6 week-old mice used for Western blot. 
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General Discussion 
 Although ovarian GCTs generally have a good prognosis particularly in comparison to 
epithelial ovarian tumors, 80% of women with advanced-stage GCT die from recurrent disease 
(45), which can occur up to 40 years after initial diagnosis and treatment (46).  Despite this, 
few studies have focused on investigating GCT disease and consequently, the pathogenesis of 
GCT remains unclear.  In order to improve the prognosis for women with advanced-stage or 
recurrent disease, the first step would be to better understand its molecular pathogenesis by 
identifying oncogenic pathways and/or genetic alterations that lead to GCT development.      
 An important advance in the study of GCT pathogenesis came with the discovery of a 
somatic mutation in FOXL2 402C!G (C134W) in nearly all adult-type GCTs that is absent in 
other ovarian and SCSTs (6, 67, 69).  Although FOXL2 is a transcription factor that is known 
to play an important role in normal granulosa cell development, the molecular implications of 
this mutation and its role in GCT pathogenesis have yet to be revealed (6, 67, 69).  
 One limitation of this study is the lack of FOXL2 mutation in the PCA model of GCT.  
Why this seemingly pathognomonic mutation for adult-type GCT is not exhibited in the PCA 
GCT model is not clear.  Initially, we wanted to validate PCA as a genuine model for GCT.  A 
veterinary pathologist confirmed by histological analyses (based on tissue and cell 
morphologies and immunohistochemistry markers for GCT) that PCA mice did in fact develop 
GCTs.  It was not possible however to further categorize GCTs as either adult or juvenile-type 
because the criteria established for the diagnosis of human GCTs did not apply to the mouse 
model.  Despite the many similarities between the PCA mouse model and the advanced 
disease in women at biological and molecular levels (112), perhaps GCT in the PCA model 
remains a separate disease from the disease in humans and therefore does not express the 
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FOXL2 mutation.  The next logical step would then be to create an animal model that exhibits 
the FOXL2 mutation in granulosa cells and determine whether the mutation alone is sufficient 
for GCT development (6).  If we are able to experimentally induce this mutation (alone or in 
combination with other mutations) and it leads to GCT development, then we would be in 
possession of a more genetically accurate animal model.  We would also be one step closer to 
understanding the pathogenesis of GCT and ultimately identifying novel therapeutic targets.   
 Animal models can serve as powerful tools in which new pharmacological agents and 
targets can be tested.  Although several mouse models of GCT have been generated, including 
inhibin-deficient mice or mice overexpresssing LH, few models have been able to replicate the 
disease in women at cellular and biological levels.  For example, while the inhibin-deficient 
mouse model developed invasive SCSTs with 100% penetrance (64), women with GCTs have 
very high serum inhibin levels that are used as tumor markers for recurrent disease (6).  As 
such, this represents an important biological difference between the mouse model and the 
human disease and puts into question the relevance of this particular model.       
 The novel PCA model presents an interesting alternative to the previously described 
mouse models.  100% of PCA mice developed bilateral GCTs perinatally that rapidly grew 
causing abdominal distension by 5 weeks of age.  This high level of penetrance facilitated the 
acquisition of test subjects with the desired phenotype and the early onset of disease reduced 
the delay to obtain tissue samples.  On the other hand, due to the high level of tumor 
aggressivity, by 8 weeks of age all animals receiving saline had died from tumor-related 
causes, which greatly limited the timeframe in which we could study the effects of treatment 
on tumor growth in comparison to control animals.    
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 An important feature of GCT disease is tumor vascularization (11, 13, 14).  VEGF, a 
key mediator of angiogenesis, is highly expressed in nearly all GCTs in endothelial and 
granulosa cells in primary and recurrent GCTs and is positively correlated with tumor 
microvessel density and the expression of VEGFR2 (13). Also, elevated serum levels of 
VEGF detected in patients with GCT were found to drop significantly after tumor removal 
(14).  These results strongly suggest that VEGF contributes to the developed tumor 
vasculature in GCTs and that it could represent a valid therapeutic target for the treatment of 
GCT.  Although numerous angiogenic inhibitors have been created to target either VEGF or 
VEGFR2 and have shown varying degrees of efficacy in the treatment of different tumor 
types, monoclonal anti-VEGFA antibodies have overall shown the most potential (4, 80, 82, 
123, 126, 127).  Bevacizumab is the most popular anti-VEGFA antibody that has been 
approved for the treatment of various cancers that is commonly administered by IV injection 
(145).  For this project, anti-VEGFA antibody was administered by IP injection.  This route of 
administration was chosen based on a handful of pharmacological studies that demonstrated 
effective absorption and determined effective doses of anti-VEGF antibodies after IP 
administration in mice (165, 166).  Shah et al (165) studied the pharmacokinetics of 
bevacizumab following IP and IV administration using a murine model of ovarian cancer and 
found that bevacizumab was rapidly absorbed after IP injection with bioavailability reaching 
92.8%.  This group also demonstrated that both routes of administration significantly 
increased survival time (with no significant differences in survival between the two groups 
treated IV or IP)(165).  Mordenti et al (166) evaluated the relationship between concentration 
and response after IP injection of a murine anti-VEGF mAb in tumor-bearing nude mice.  
Tumor suppression was achieved at doses equal to or greater than 2.5mg/kg and the average 
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trough plasma concentration was found to be 30ug/ml (166).  Both of these studies served to 
provide the groundwork for future studies that could focus on the clinical outcomes of anti-
VEGF antibody administration by IP injection.   
 A second reason for choosing to administer anti-VEGFA antibody by IP administration 
was based on the biological behavior of ovarian tumors (167).  Although in human medicine 
the standard approach for the treatment of ovarian cancer is IV infusion of chemotherapy 
drugs repeatedly over 5-8 cycles, recent studies have investigated the potential of IP 
administration based on the fact that these tumors tend to confine themselves to the surface of 
the peritoneal cavity (167).  IP infusion of a drug directly into the peritoneal cavity should 
theoretically increase the concentration of drug reaching the target tumor cells and therefore 
exert a more important effect.  Jaaback et al (167) performed a review of randomized trials 
involving women who were being treated for newly-diagnosed primary epithelial ovarian 
cancer with IV alone or IV and IP chemotherapy following primary cytoreductive surgery.  
They discovered that IP combined with IV chemotherapy increased overall survival and 
progression-free survival in comparison to IV alone (167).  Although not entirely conclusive, 
these results suggested that IP injection promotes a more efficient drug delivery to the target 
organ and consequently delays disease progression and improves survival.  However, only 
future studies that are able to quantify the concentration of drug that is found within the target 
cells after IP administration relative to the administered dose and the effect on tumor growth 
would be able to provide more definitive answers.    
 This project aimed to investigate the potential of a monoclonal anti-VEGFA antibody 
for the treatment of GCT in the PCA preclinical model.  This study’s objectives were to 
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evaluate the effect of anti-VEGFA antibody on tumor growth, survival, cell proliferation and 
apoptosis, tumor microvessel density, and activation of VEGFR2 signaling pathway effectors.   
 Anti-VEGFA antibody significantly reduced tumor growth and improved survival in 
treated mice in comparison to controls.  A likely explanation for the reduction in tumor growth 
came from analyses of GCT tumors in which significant decreases in cell proliferation and 
tumor microvessel density were found in treated tumors relative to controls.  Given the well-
established role of VEGF in endothelial and granulosa cell proliferation, these findings did not 
necessarily come as a surprise (82, 83, 87, 168-170).  Preventing VEGF binding to its receptor 
would then logically prevent the activation of downstream signaling effectors involved in cell 
proliferation (such as MAPK).  This was confirmed by an immunoblotting experiment in 
which significantly reduced MAPK activation was found.  By immunohistochemistry, MAPK 
activation seemed to occur in both endothelial and granulosa cells.  In addition, the reduction 
in microvessel density suggests that anti-VEGFA treatment prevented development of the 
tumor microvasculature thereby limiting the delivery of nutrients and oxygen to tumor cells, 
resulting in decreased cell proliferation.    
 Unexpectedly, anti-VEGFA treatment did not have a significant effect on apoptosis 
despite the fact that VEGF signaling is involved in cell survival (14, 79, 82, 83, 87).  This was 
further confirmed by immunoblotting, where no significant reduction in AKT activation, a 
VEGFR2 signaling effector involved in cell survival, was found, relative to controls.   It is 
possible that tumor cells acquired a resistance to apoptosis by any number of mechanisms 
(such as overexpression of anti-apoptotic molecules, downregulation/mutation of pro-
apoptotic genes, etc.) (171) and that despite the absence of an important survival factor such as 
VEGFA, they still found the means to survive.   
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 One limitation of the present study was the absence of phospho-VEGFR2 signal at two 
different phosphorylation sites in neither the control nor the treated group.  These results 
would have served to confirm the inhibition of VEGF binding to its receptor represented as a 
reduction in VEGFR2 phosphorylation in treated tumors compared to controls.  The failure to 
detect any signal might be on account of the short duration of receptor phosphorylation (i.e. 
perhaps VEGFA binding to VEGFR2 induces an immediate spike in receptor phosphorylation 
that tapers off after a few minutes), which limits the timeframe for detection by 
immunoblotting.  Another possibility might be that the antibodies used were simply not 
sensitive enough to detect the activation levels of VEGFR2 in this tumor model.   
Given the effectiveness of anti-VEGFA antibody at reducing tumor growth and 
extending survival in the PCA model, future experiments might look at combining anti-
VEGFA antibody with chemotherapy in PCA mice in order to establish optimal treatment 
schedules.  A hypothesis proposed by Jain et al (163) states that anti-VEGF therapy 
normalizes the tumor vasculature, resulting in improved oxygenation and delivery of cytotoxic 
agents.  By combining the two therapies, both endothelial and granulosa tumor cells are 
targeted and destroyed, which should theoretically improve treatment efficacy.  However, no 
studies to date have evaluated whether priming tumor blood vessels with anti-VEGFA 
antibody does in fact improve chemotherapy delivery to the tumor.   
Although we still have a long way to go before establishing standardized treatment 
regimens for advanced or recurrent GCT disease, the present study has provided many reasons 
to be optimistic and serves as a starting point for future studies. 
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Conclusion 
 These experiments revealed that anti-VEGFA therapy is effective for the treatment of 
GCT in the PCA preclinical model.  Administration of anti-VEGFA antibody significantly 
reduced tumor size and extended survival in treated animals relative to controls.  The 
reduction in tumor weight was attributed to a reduction in cell proliferation and microvessel 
density via inhibition of the VEGFR2-MAPK signaling pathway in treated tumors in 
comparison to controls.  Anti-VEGFA therapy did not have a significant effect on apoptosis.  
These findings represent important advances in the field of GCT therapy that could eventually 
apply to the development of standardized treatment protocols for recurrent or advanced 
disease in women.  
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